AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33455902
Drug: HeartBot app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: HeartBot app intervention for 21 days, 30 minutes daily.
Trial: 33459278
Drug: Ghya Bharari
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ghya Bharari Ekatra (GBE) intervention delivered over 6 weekly sessions by lay peer educators; included components on relationship quality, resilience, communication, self-esteem, sexual communication, and norms around IPV.
Trial: 33460016
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered semaglutide 7 mg
Trial: 33460016
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered semaglutide 14 mg
Trial: 33461307
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day of long chain n-3 polyunsaturated fatty acids (fish oil capsules) for 6 weeks
Trial: 33463373
Drug: Cabazitaxel (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel (25 mg/m²)
Trial: 33463384
Drug: Slow and
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow and deep breathing intervention, details on dosage and duration not available.
Trial: 33463681
Drug: EHR-integrated digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EHR-integrated digital health tools (checklist and video) administered on a mobile device via a patient portal or web-based survey at least 24 hours prior to anticipated discharge.
Trial: 33464021
Drug: Zidovudine (ZDV),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV), Lamivudine (3TC), and Lopinavir/Ritonavir (LPV/r) syrup for 48 weeks according to WHO weight band dosing.
Trial: 33464147
Drug: Subcutaneous tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous tocilizumab treatment
Trial: 33465022
Drug: Traditional treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatments (e.g. opioids, NSAIDs)
Trial: 33465034
Drug: Behavioral modifications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral modifications due to the pandemic (e.g., using hand sanitizers, avoiding public transport, preferring outdoor venues)
Trial: 33468698
Drug: DNA vaccine
RxNorm normalized name: HTNV DNA vaccine
DrugBank: Hantaan virus DNA vaccine (DB17808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA vaccine pBI-11 targeting HPV16 and HPV18 E6 and E7 proteins
Trial: 33468698
Drug: DNA vaccine
RxNorm normalized name: HTNV DNA vaccine
DrugBank: Hantaan virus DNA vaccine (DB17808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA vaccine pBI-10.1 utilizing native viral sequences
Trial: 33469316
Drug: Tezepelumab 70
RxNorm normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tezepelumab 70 mg Q4W
Trial: 33469316
Drug: Tezepelumab 280
RxNorm normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tezepelumab 280 mg Q2W
Trial: 33469328
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine biosimilar Ezelin (EZL)
Trial: 33469328
Drug: Originator insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Originator insulin glargine Lantus (LAN)
Trial: 33469351
Drug: Active low-level
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active low-level laser therapy + moderate-intensity aerobic exercise
Trial: 33469351
Drug: Placebo low-level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo low-level laser therapy + moderate-intensity aerobic exercise
Trial: 33469828
Drug: Persistently Gd-enhancing
RxNorm normalized name: Gd-HPDO3A
DrugBank: Gadoteridol (DB00597)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Persistently Gd-enhancing lesions (PE group) in aquaporin-4-positive, first-attack, transverse myelitis or high-dose steroid treatment subgroup
Trial: 33469852
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of autologous bone marrow-derived mesenchymal stem cells (MSCs) (1 × 10)
Trial: 33470662
Drug: Minimizing time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimizing time to antimicrobial therapy
Trial: 33470662
Drug: Appropriate antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate antibiotic choice
Trial: 33470662
Drug: Antimicrobial dosing
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial dosing
Trial: 33470662
Drug: De-escalation of
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De-escalation of therapy
Trial: 33470897
Drug: Aminolevulinic acid
RxNorm normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminolevulinic acid topical application and 633 nm red light illumination
Trial: 33471949
Drug: docetaxel cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel cisplatin 5-fluorouracil induction chemotherapy
Trial: 33472666
Drug: Axitinib 3
RxNorm normalized name: Axitinib 3 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib 3 mg twice daily (MTD)
Trial: 33472666
Drug: Axitinib 1
RxNorm normalized name: axitinib 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib 1 mg twice daily
Trial: 33472666
Drug: Axitinib 2
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib 2 mg twice daily
Trial: 33472666
Drug: Axitinib 3
RxNorm normalized name: Axitinib 3 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib 3 mg twice daily
Trial: 33473101
Drug: Personalized neoantigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized neoantigen peptide-pulsed autologous dendritic cell vaccine
Trial: 33474638
Drug: Energy-restricted treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy-restricted treatment
Trial: 33474858
Drug: Aspirin provocation
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin provocation
Trial: 33474858
Drug: Drug provocation
RxNorm normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (ROUGE PROVOCATION) - RED]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug provocation
Trial: 33474976
Drug: Initial hs-cTnT
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial hs-cTnT measures below the limit of quantification (LOQ: 6 ng/L)
Trial: 33475793
Drug: Intrathecal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal administration of 50 mg of hyperbaric prilocaine
Trial: 33476432
Drug: Voxelotor treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voxelotor treatment, dosage and duration not available
Trial: 33477665
Drug: Behavior related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior related to treatment of LUTS
Trial: 33477964
Drug: Customized human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Customized human milk fortification using a multi-nutrient fortifier and modular supplements of protein and fat.
Trial: 33477979
Drug: Cemiplimab (monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemiplimab (monoclonal antibody targeting PD1), administered for ten cycles
Trial: 33478647
Drug: Transcatheter treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter treatment of secondary tricuspid regurgitation
Trial: 33478921
Drug: Carfilzomib in
RxNorm normalized name: carfilzomib Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib in combination with bendamustine and rituximab
Trial: 33479501
Drug: NeoVax, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeoVax, a long-peptide vaccine targeting up to 20 personal neoantigens per patient
Trial: 33479856
Drug: LY3295668 erbumine
RxNorm normalized name: Perindopril Erbumine
DrugBank: Perindopril (DB00790)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LY3295668 erbumine 25 mg BID
Trial: 33479856
Drug: LY3295668 erbumine
RxNorm normalized name: Perindopril Erbumine
DrugBank: Perindopril (DB00790)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LY3295668 erbumine 50 mg BID
Trial: 33479856
Drug: LY3295668 erbumine
RxNorm normalized name: Perindopril Erbumine
DrugBank: Perindopril (DB00790)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LY3295668 erbumine 75 mg BID
Trial: 33479856
Drug: LY3295668 erbumine
RxNorm normalized name: Perindopril Erbumine
DrugBank: Perindopril (DB00790)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LY3295668 erbumine (all doses)
Trial: 33480607
Drug: Conservative physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative physical therapy (10 sessions)
Trial: 33480608
Drug: Paracetamol (analgesic)
RxNorm normalized name: Analgesic Balm GRX
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol (analgesic)
Trial: 33480854
Drug: DMT app
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMT app assessing impulsivity in daily life
Trial: 33481332
Drug: Prescribed light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed light exercise (30 minutes of daily light exercise)
Trial: 33481403
Drug: Intraoperative methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative methadone (0.1 mg/kg, maximum 5 mg) and postoperative every 12 hours for 3-5 doses
Trial: 33481672
Drug: Prior oral
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior oral contraceptive use
Trial: 33481672
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no prior oral contraceptive use)
Trial: 33483802
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine infusion (0.15 mg/kg/h titrated toward 0.6 mg/kg/h)
Trial: 33484136
Drug: Maternal lutein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal lutein and zeaxanthin intake during pregnancy (mean daily intake: 2.6 mg)
Trial: 33485301
Drug: EFV 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EFV 400 mg combined with tenofovir (TDF) and lamivudine (3TC) for 48 weeks
Trial: 33485708
Drug: Individualized food-based
RxNorm normalized name: food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized food-based nutrition intervention program (6 months duration, caloric restriction of 500-1000 kcal/d when applicable, protein intake of 1.2-1.5 g/kgBW/d, 5-9 servings/day of fruits and vegetables)
Trial: 33485799
Drug: Imiglucerase treatment
RxNorm normalized name: Imiglucerase
DrugBank: Imiglucerase (DB00053)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiglucerase treatment
Trial: 33486223
Drug: Daily egg
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily egg intake
Trial: 33486971
Drug: Noninvasive ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive ultrasound therapy
Trial: 33487029
Drug: Second-line antiretroviral
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line antiretroviral (ART) treatment
Trial: 33487127
Drug: 1,25-dihydroxyvitamin D
RxNorm normalized name: 1,25-dihydroxyvitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25-dihydroxyvitamin D (1,25(OH)D); specific dosage and duration not mentioned
Trial: 33487279
Drug: Triheptanoin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triheptanoin treatment for 78 weeks
Trial: 33487468
Drug: 1 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg CV7202
Trial: 33487468
Drug: 2 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg CV7202
Trial: 33487468
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg CV7202
Trial: 33487468
Drug: 1 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg CV7202 (after two doses)
Trial: 33487468
Drug: 2 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg CV7202 (after two doses)
Trial: 33487824
Drug: Articaine 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articaine 2% (40 ml)
Trial: 33487824
Drug: Articaine 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articaine 2% mixed with dexmedetomidine (1 μg.kg) (40 ml)
Trial: 33488576
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Hiltonol and vaccine antigens only)
Trial: 33489806
Drug: Treatment patterns
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment patterns (type/duration, number of lines, completion rate)
Trial: 33489806
Drug: Early-stage treatment
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early-stage treatment (starting from 1 December 2010)
Trial: 33489806
Drug: Kaplan-Meier curves
RxNorm normalized name: meyer lemon extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kaplan-Meier curves for treatment duration and overall survival
Trial: 33490640
Drug: Mobile outreach
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile outreach team approach with oral anti-TB treatment under DOTS
Trial: 33490640
Drug: Facility-based DOTS
RxNorm normalized name: D3 Dots
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facility-based DOTS treatment according to WHO recommendations
Trial: 33490707
Drug: Stereotactic ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic ablative body radiotherapy (SABR) - 20Gy single fraction followed by pembrolizumab - 200 mg every 3 weeks for 8 cycles
Trial: 35618285
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg) intravenously every 21 days
Trial: 33491668
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of allogeneic human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) at a dosage of 1 × 10^6 to 3 × 10^6 cells/kg, administered as 3 injections every 2 weeks for 8-24 months.
Trial: 33492239
Drug: Weekly subcutaneously
RxNorm normalized name: Weekly Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly subcutaneously administered methotrexate
Trial: 33492239
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral azathioprine or 6-mercaptopurine
Trial: 33492239
Drug: Subcutaneously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously administered adalimumab (ADA)
Trial: 33492438
Drug: AR-42, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR-42, 60 mg three times weekly for 3 weeks of a 28-day cycle
Trial: 33492986
Drug: Toripalimab 3
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab 3 mg/kg every 2 weeks via intravenous infusion until disease progression or unacceptable toxicity
Trial: 33492986
Drug: Toripalimab 3
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab 3 mg/kg every 2 weeks via intravenous infusion
Trial: 33493312
Drug: Intravenous golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous golimumab (80 mg/m2 at weeks 0, 4, then every 8 weeks through week 52 plus MTX weekly through week 28)
Trial: 33493312
Drug: Intravenous golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous golimumab
Trial: 33493392
Drug: Ivosidenib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivosidenib (100 mg twice daily and 300-1200 mg once daily)
Trial: 33493590
Drug: Preoperative lymphocyte
RxNorm normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative lymphocyte count <0.6 (×10^9/L)
Trial: 33493697
Drug: Direct acting
RxNorm normalized name: DIRECT ACTING ANTIVIRALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct acting antiviral agents (DAAs) leading to sustained virologic response (SVR)
Trial: 33493822
Drug: Apraxia of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apraxia of Speech Rating Scale (ASRS) administered by five speech-language pathologists (SLPs)
Trial: 33494963
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose recombinant full-length circumsporozoite protein-based vaccine with GLA-LSQ adjuvant
Trial: 33495312
Drug: All-trans retinoic
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans retinoic acid (ATRA) plus tranylcypromine (TCP) at three dose levels: 10 mg twice daily, 20 mg twice daily, and 30 mg twice daily.
Trial: 33495476
Drug: Prior treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior treatments
Trial: 33495752
Drug: Ivermectin 400
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin 400 mcg/kg, single dose
Trial: 35244520
Drug: Pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 10 mg/kg every 2 weeks for up to 2 years
Trial: 33496677
Drug: Fitbit Zip
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fitbit Zip activity tracker worn daily for 8 weeks (2 weeks prior to surgery and 6 weeks post-surgery)
Trial: 33496747
Drug: Lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25 mg daily for 14 days per cycle combined with 8 cycles of CHOP21
Trial: 33496906
Drug: Fluid challenge
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid challenge (500 mL gelatin over 15 min)
Trial: 33498797
Drug: Palbociclib +
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib + Letrozole (P+L)
Trial: 33501400
Drug: 6 weekly
RxNorm normalized name: tobramycin 28 MG inhalation powder 56 Weekly Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 weekly doses of lyophilized fecal microbiota product from healthy donors
Trial: 33502111
Drug: Oral tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tacrolimus (0.03 mg/kg) administered twice daily starting 3 days prior to transplant
Trial: 33502111
Drug: Dosing simulation
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosing simulation strategy based on observed tacrolimus concentration
Trial: 33502567
Drug: Ultra-Low Doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-Low Doses of Therapy with Radiation (ULTRA-COVID)
Trial: 33503046
Drug: Increased PPI
RxNorm normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased PPI doses or use of PPIs not metabolized by CYP2C19 (rabeprazole)
Trial: 33503342
Drug: Levonorgestrel IUD
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel IUD (52-mg)
Trial: 33505715
Drug: Conjunctival autografting
RxNorm normalized name: Sus scrofa conjunctiva preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjunctival autografting augmented with topical application of MMC (0.2 mg/mL)
Trial: 33505726
Drug: 2 l/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 l/min supplemental oxygen during bronchoscopy
Trial: 33505726
Drug: No oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oxygen administration during bronchoscopy
Trial: 33506177
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment (G1)
Trial: 33506571
Drug: Capmatinib 400
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capmatinib 400 mg twice daily
Trial: 33506635
Drug: Molidustat (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molidustat (75 mg once daily, adjusted to maintain Hb target of ≥10.0 to <12.0 g/dL)
Trial: 33506635
Drug: Molidustat (dose-titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molidustat (dose-titrated for 24 weeks)
Trial: 33507454
Drug: Mavorixafor 400
RxNorm normalized name: Mavorixafor
DrugBank: Mavorixafor (DB05501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavorixafor 400 mg daily plus nivolumab 240 mg every 2 weeks